title: Toward Optimum Benefit-Risk and Reduced Access Lag For Cancer Drugs in Asia: A Global Development Framework Guided by Clinical Pharmacology Principles.
authors.affiliation: Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited), Cambridge, Massachusetts, USA.
authors.forename: K
authors.initials: K
authors.lastname: Venkatakrishnan
authors.affiliation: Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited), Cambridge, Massachusetts, USA.
authors.forename: C
authors.initials: C
authors.lastname: Burgess
authors.affiliation: Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited), Cambridge, Massachusetts, USA.
authors.forename: N
authors.initials: N
authors.lastname: Gupta
authors.affiliation: Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited), Cambridge, Massachusetts, USA.
authors.forename: A
authors.initials: A
authors.lastname: Suri
authors.affiliation: Takeda Pharmaceutical Company Limited, Tokyo, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Takubo
authors.affiliation: Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited), Cambridge, Massachusetts, USA.
authors.forename: X
authors.initials: X
authors.lastname: Zhou
authors.affiliation: Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited), Cambridge, Massachusetts, USA.
authors.forename: D
authors.initials: D
authors.lastname: DeMuria
authors.affiliation: Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited), Cambridge, Massachusetts, USA.
authors.forename: M
authors.initials: M
authors.lastname: Lehnert
authors.affiliation: Takeda Pharmaceutical Company Limited, Tokyo, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Takeyama
authors.affiliation: Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited), Cambridge, Massachusetts, USA.
authors.forename: S
authors.initials: S
authors.lastname: Singhvi
authors.affiliation: Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited), Cambridge, Massachusetts, USA.
authors.forename: A
authors.initials: A
authors.lastname: Milton
mesh_terms: D000970:Antineoplastic Agents / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D001208:Asia; D004305:Dose-Response Relationship, Drug; D006297:Health Services Accessibility; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D017410:Practice Guidelines as Topic; D018570:Risk Assessment
chemical_list: D000970:Antineoplastic Agents
references.citation: Drug Metab Rev. 2003 May-Aug;35(2-3):99-106
references.pmid: 12959412
references.citation: Clin Pharmacol Ther. 2005 Aug;78(2):102-13
references.pmid: 16084844
references.citation: Nature. 2005 Oct 27;437(7063):1299-320
references.pmid: 16255080
references.citation: Xenobiotica. 2006 Jun;36(6):499-513
references.pmid: 16865818
references.citation: Clin Pharmacol Ther. 2008 Sep;84(3):347-61
references.pmid: 18231117
references.citation: Clin Pharmacol Ther. 2008 Sep;84(3):417-23
references.pmid: 18615002
references.citation: Clin Pharmacol Ther. 2008 Sep;84(3):287-94
references.pmid: 18714314
references.citation: Br J Cancer. 2008 Dec 2;99(11):1757-62
references.pmid: 18985035
references.citation: Clin Pharmacol Ther. 2010 Mar;87(3):362-6
references.pmid: 20107436
references.citation: J Clin Pharmacol. 2010 Aug;50(8):929-40
references.pmid: 20173083
references.citation: Clin Pharmacol Ther. 2010 Jun;87(6):714-20
references.pmid: 20410879
references.citation: Clin Pharmacokinet. 2010 Nov;49(11):703-27
references.pmid: 20923246
references.citation: Paediatr Anaesth. 2011 Mar;21(3):214-21
references.pmid: 21244569
references.citation: Invest New Drugs. 2011 Aug;29(4):706-12
references.pmid: 21286780
references.citation: J Clin Oncol. 2011 Apr 1;29(10):1271-9
references.pmid: 21383285
references.citation: PLoS One. 2011 Apr 05;6(4):e18312
references.pmid: 21483678
references.citation: Jpn J Clin Oncol. 2011 Jun;41(6):825-31
references.pmid: 21531734
references.citation: Drug Metab Pharmacokinet. 2012;27(1):9-54
references.pmid: 22123129
references.citation: Lancet Oncol. 2012 Aug;13(8):790-801
references.pmid: 22658655
references.citation: Clin Cancer Res. 2012 Sep 1;18(17):4764-74
references.pmid: 22753585
references.citation: Clin Cancer Res. 2012 Sep 1;18(17):4775-84
references.pmid: 22767670
references.citation: J Biopharm Stat. 2012 Sep;22(5):977-87
references.pmid: 22946944
references.citation: J Biopharm Stat. 2012 Sep;22(5):1060-73
references.pmid: 22946950
references.citation: Jpn J Clin Oncol. 2012 Dec;42(12):1222-31
references.pmid: 23100603
references.citation: Yonsei Med J. 2013 Jan 1;54(1):1-14
references.pmid: 23225792
references.citation: Ann Surg Oncol. 2013 Jul;20(7):2328-38
references.pmid: 23340695
references.citation: Ann Oncol. 2013 Jun;24(6):1653-9
references.pmid: 23413279
references.citation: Clin Pharmacol Ther. 2013 Jul;94(1):37-51
references.pmid: 23443754
references.citation: Clin Pharmacol Ther. 2013 Aug;94(2):230-42
references.pmid: 23588316
references.citation: Clin Pharmacokinet. 2013 Dec;52(12):1085-100
references.pmid: 23818090
references.citation: Clin Pharmacol Ther. 2013 Aug;94(2):195-8
references.pmid: 23872835
references.citation: Clin Pharmacol Ther. 2014 May;95(5):533-41
references.pmid: 24213186
references.citation: J Clin Pharmacol. 2014 May;54(5):483-94
references.pmid: 24242979
references.citation: Clin Pharmacol Ther. 2014 May;95(5):542-9
references.pmid: 24281222
references.citation: BMC Med. 2014 Jan 08;12:3
references.pmid: 24400922
references.citation: Cancer Chemother Pharmacol. 2014 Apr;73(4):779-88
references.pmid: 24519753
references.citation: Cancer Chemother Pharmacol. 2014 Apr;73(4):759-70
references.pmid: 24522402
references.citation: Indian J Med Res. 2014 Jan;139(1):27-65
references.pmid: 24604039
references.citation: Invest New Drugs. 2014 Aug;32(4):661-9
references.pmid: 24615632
references.citation: Invest New Drugs. 2014 Dec;32(6):1181-7
references.pmid: 24879333
references.citation: Clin Pharmacol Ther. 2014 Nov;96(5):559-71
references.pmid: 25006877
references.citation: Clin Pharmacol Ther. 2014 Nov;96(5):572-9
references.pmid: 25105705
references.citation: Int J Oncol. 2014 Oct;45(4):1381-90
references.pmid: 25175642
references.citation: Int J Cancer. 2015 Mar 1;136(5):E359-86
references.pmid: 25220842
references.citation: J Clin Pharmacol. 2015 Mar;55(3):336-47
references.pmid: 25302940
references.citation: J Clin Pharmacol. 2015 May;55(5):481-9
references.pmid: 25560978
references.citation: Cancer Chemother Pharmacol. 2015 Mar;75(3):579-86
references.pmid: 25577133
references.citation: J Clin Oncol. 2015 Apr 10;33(11):1235-42
references.pmid: 25624441
references.citation: Clin Pharmacol Ther. 2015 Mar;97(3):234-46
references.pmid: 25669457
references.citation: Clin Pharmacol Ther. 2015 Mar;97(3):218-20
references.pmid: 25669642
references.citation: Clin Pharmacol Ther. 2015 Mar;97(3):263-73
references.pmid: 25669658
references.citation: Clin Pharmacol Ther. 2015 Mar;97(3):247-62
references.pmid: 25670209
references.citation: Clin Pharmacol Ther. 2015 Jan;97(1):37-54
references.pmid: 25670382
references.citation: Expert Opin Drug Metab Toxicol. 2015 May;11(5):835-42
references.pmid: 25732197
references.citation: Int J Clin Oncol. 2015 Dec;20(6):1072-80
references.pmid: 25837976
references.citation: J Clin Oncol. 2015 Jun 20;33(18):2051-61
references.pmid: 25918301
references.citation: BMC Res Notes. 2015 Apr 30;8:176
references.pmid: 25925844
references.citation: Br J Haematol. 2015 Oct;171(1):109-15
references.pmid: 26033531
references.citation: Invest New Drugs. 2015 Aug;33(4):942-53
references.pmid: 26084989
references.citation: Clin Pharmacol Ther. 2015 Nov;98(5):486-8
references.pmid: 26239646
references.citation: Haematologica. 2016 Jan;101(1):e24-6
references.pmid: 26405151
references.citation: Pharmacogenomics J. 2016 Nov;16(6):536-539
references.pmid: 26503813
references.citation: Clin Cancer Res. 2016 Mar 15;22(6):1318-24
references.pmid: 26597302
references.citation: Am J Cancer Res. 2015 Aug 15;5(9):2892-911
references.pmid: 26609494
references.citation: Ther Innov Regul Sci. 2014 May;48(3):393-403
references.pmid: 30235544